Armando S.
- Country
- Italy
- Department
- U.O. di Oncologia Medica ed Ematologia
Research Overview
- A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Safety, Pharmacokinetics, and Efficacy of BAY 2416964 (AhR Inhibitor) and Pembrolizumab in Adults with Advanced Solid Tumors
- Evaluation of AMG 193 Combined with Additional Therapies in Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous MTAP-Deletion
Data & Insights
Has run more than one trial at 576 of 895 partner sites.
Specializations
Solid Tumor Oncology
The investigator concentrates on the therapeutic management of advanced solid malignancies, emphasizing molecularly driven treatment strategies across diverse organ sites.
- Non‑small cell lung cancer
- Metastatic breast cancer
- Gastro‑intestinal adenocarcinomas
- Melanoma
- Rare squamous cell carcinomas (anal, cervical, vulvar)
Research integrates targeted agents, immunotherapies, and biomarker‑guided patient selection.
Hematologic Malignancies
Focused on innovative approaches for blood‑derived cancers, the investigator addresses both acute and chronic disease entities.
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Diffuse large B‑cell lymphoma
- Multiple myeloma
- Myelodysplastic syndromes
Efforts prioritize genomic profiling, cellular therapies, and resistance mitigation.
Liver Disease & Metabolic Disorders
In the hepatology arena, the investigator explores therapies for metabolic liver injury and primary liver cancers.
- Non‑alcoholic steatohepatitis (NASH)
- Hepatocellular carcinoma
- Cholangiocarcinoma
- Metabolic dysfunction‑associated steatohepatitis (MASH)
- Fibrosis regression strategies
Studies integrate metabolic risk modification with disease‑modifying agents.
Autoimmune & Inflammatory Diseases
The investigator’s portfolio includes chronic immune‑mediated conditions that require targeted immunomodulation.
- Systemic lupus erythematosus
- Rheumatoid arthritis
- Atopic dermatitis
- Inflammatory bowel disease (Crohn’s & ulcerative colitis)
- Psoriasis
Research emphasizes pathway‑specific biologics and safety in refractory populations.
Cardiovascular & Thrombotic Disorders
Cardiovascular investigations target both atherosclerotic disease and arrhythmic complications.
- Atrial fibrillation
- Heart failure with preserved ejection fraction
- Atherosclerotic cardiovascular disease
- Thromboembolic prevention
- Cardiovascular outcomes after myocardial infarction
Efforts focus on novel anticoagulants, risk‑reduction strategies, and mechanistic biomarkers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
